Table 2.
Number of Newly Diagnosed Patients with Hepatocellular Carcinoma by Barcelona Clinic Liver Cancer (BCLC) Stages During the Period of February to May 2019 and February to May 2020
| Country (Number of Institutions) | BCLC Stage | Pre-Pandemic Perioda n (%) | Pandemic Period n (%) | Percentage Changeb |
|---|---|---|---|---|
| All countries | 0/A | 853 (34.1) | 751 (37.2) | −12.0 |
| B | 824 (33.0) | 638 (31.6) | −22.6 | |
| C | 821 (32.9) | 631 (31.2) | −23.1 | |
| Australia (N = 1) | 0/A | 17 (34.0) | 15 (31.3) | −11.8 |
| B | 22 (44.0) | 18 (37.5) | −18.2 | |
| C | 11 (22.0) | 15 (31.3) | 36.4 | |
| Brunei (N = 1) | 0/A | 2 (40.0) | 2 (40.0) | 0.0 |
| B | 2 (40.0) | 2 (40.0) | 0.0 | |
| C | 1 (20.0) | 1 (20.0) | 0.0 | |
| China (N = 2) | 0/A | 284 (37.2) | 238 (40.1) | −16.2 |
| B | 141 (18.5) | 106 (17.8) | −24.8 | |
| C | 338 (44.3) | 250 (42.1) | −26.0 | |
| Hong Kong (N = 1) | 0/A | 36 (23.5) | 20 (23.5) | −44.4 |
| B | 63 (41.2) | 35 (41.2) | −44.4 | |
| C | 54 (35.3) | 30 (35.3) | −44.4 | |
| Indonesia (N = 1) | 0/A | 2 (33.3) | 1 (33.3) | −50.0 |
| B | 2 (33.3) | 1 (33.3) | −50.0 | |
| C | 2 (33.3) | 1 (33.3) | −50.0 | |
| Japan (N = 3) | 0/A | 56 (60.9) | 54 (61.4) | −3.6 |
| B | 18 (19.6) | 17 (19.3) | −5.6 | |
| C | 18 (19.6) | 17 (19.3) | −5.6 | |
| Malaysia (N = 1) | 0/A | 17 (42.5) | 62 (62.0) | 264.7 |
| B | 10 (25.0) | 10 (10.0) | 0.0 | |
| C | 13 (32.5) | 28 (28.0) | 115.4 | |
| Mongolia (N = 1) | 0/A | 8 (13.6) | 6 (14.3) | −25.0 |
| B | 20 (33.9) | 14 (33.3) | −30.0 | |
| C | 31 (52.5) | 22 (52.4) | −29.0 | |
| Myanmar (N = 1) | 0/A | 30 (30.0) | 10 (28.6) | −66.7 |
| B | 40 (40.0) | 15 (42.9) | −62.5 | |
| C | 30 (30.0) | 10 (28.6) | −66.7 | |
| Philippines (N = 4) | 0/A | 31 (37.8) | 7 (25.9) | −77.4 |
| B | 27 (32.9) | 11 (40.7) | −59.3 | |
| C | 24 (29.3) | 9 (33.3) | −62.5 | |
| Singapore (N = 2) | 0/A | 8 (18.2) | 14 (30.4) | 75.0 |
| B | 6 (13.6) | 17 (37.0) | 183.3 | |
| C | 30 (68.2) | 15 (32.6) | −50.0 | |
| South Korea (N = 3) | 0/A | 32 (38.1) | 28 (35.0) | −12.5 |
| B | 31 (36.9) | 28 (35.0) | −9.7 | |
| C | 21 (25.0) | 24 (30.0) | 14.3 | |
| Taiwan (N = 4) | 0/A | 284 (47.9) | 258 (48.8) | −9.2 |
| B | 164 (27.7) | 144 (27.2) | −12.2 | |
| C | 145 (24.5) | 127 (24.0) | −12.4 | |
| Thailand (N = 2) | 0/A | 46 (10.9) | 36 (10.7) | −21.7 |
| B | 278 (65.1) | 220 (65.1) | −20.9 | |
| C | 103 (24.1) | 82 (24.3) | −20.4 |
Notes:aMissing n are imputed based on the percentage change in the new HCC cases during the pandemic compared to the same period during the pre-pandemic. b(Pandemic n – Pre-pandemic n)/Pre-pandemic n × 100.